Skyepharma is a specialist drug delivery company developing oral and inhalation products. With a wide range of patented and proven technologies, Skyepharma helps to make good drugs better. We partner with a wide variety of companies from big Pharma, such as GlaxoSmithKline, Novartis, sanofi-aventis, AstraZeneca and Roche to a range of smaller speciality pharmaceutical companies. Skyepharma’s proprietary drug delivery technologies enable the development of new formulations of existing products as well as new chemical entities to provide a clinical benefit to patients. Skyepharma’s Geomatrix™ and Geoclock™ technologies enable controlled- or timed-release versions of immediate-release products to be developed providing advantages to both partner companies and patients. The Group’s inhalation technologies include formulation as well as device technologies and encompass metered dose inhalers and dry powder inhalers. With research and development facilities in Switzerland and manufacturing in France, Skyepharma offers a comprehensive range of services from feasibility through to commercial scale manufacture.
Show more
Saint-Quentin-Fallavier, FR
Size (employees)
108 (est)
Skyepharma was founded in 1996 and is headquartered in Saint-Quentin-Fallavier, FR
Report incorrect company information

Skyepharma Office Locations

Skyepharma has an office in Saint-Quentin-Fallavier
Saint-Quentin-Fallavier, FR (HQ)
55 Rue du Montmurier
Show all (1)
Report incorrect company information

Skyepharma Financials and Metrics

Skyepharma Financials

Skyepharma's revenue was reported to be £95.90 m in FY, 2015 which is a 29.9% increase from the previous period.

Revenue (FY, 2015)

95.9 m

Revenue growth (FY, 2014 - FY, 2015), %


Gross profit (FY, 2015)

52.8 m

Gross profit margin (FY, 2015), %

GBPFY, 2013FY, 2014FY, 2015


62.6 m73.8 m95.9 m

Revenue growth, %


Cost of goods sold

33.2 m32.9 m43.1 m

Gross profit

29.4 m40.9 m52.8 m
GBPY, 2015


888 k
Show all financial metrics
Report incorrect company information